Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node Dysfunction (PSB-AF)
A Prospective, Multicenter, Randomized Controlled Trial Evaluating the Effect of Posterosuperior Bundle Pacing on Atrial Fibrillation Prevention in Patients With Sinus Node Dysfunction
This study aims to evaluate whether posterosuperior bundle (PSB) pacing reduces the incidence of atrial fibrillation (AF) in patients with sinus node dysfunction (SND) undergoing pacemaker implantation. Approximately 300 patients will be enrolled and randomized to receive atrial pacing at either the PSB region or the right atrial appendage (RAA). The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes, as detected by device or surface electrocardiogram. Patients will be followed for up to 24 months.
研究概览
详细说明
Sinus node dysfunction (SND) is a common indication for permanent pacemaker implantation. Conventional right atrial appendage (RAA) pacing may result in delayed or dyssynchronous atrial activation, potentially increasing the risk of atrial arrhythmias. Posterosuperior bundle (PSB) pacing is a novel physiological atrial pacing approach. This study is a prospective, multicenter, open-label, randomized controlled trial. A total of approximately 300 eligible SND patients indicated for pacemaker implantation will be enrolled and randomly assigned (1:1) to PSB pacing or RAA pacing. Ventricular pacing will be performed using left bundle branch area pacing in both groups. Following implantation, the pacemaker will be programmed in DDD mode with a lower rate of 70 beats/min during daytime and 60 beats/min during nighttime. Rate-responsive pacing will be enabled by default when available; ATP will be disabled by default. Participants will be followed at 3, 6, 12, and 24 months after implantation. The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes. Secondary endpoints include atrial high-rate episodes, AF burden, pacing parameters, ECG and echocardiographic indices, laboratory findings, and mortality outcomes. Safety endpoints include procedural complications and device-related adverse events.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Zhaohui Qiu
- 电话号码:+862152039999
- 邮箱:qzh3503@shtrhospital.com
学习地点
-
-
Anhui
-
Anqing、Anhui、中国
- 尚未招聘
- China Medical University affiliated AnQing Municipal Hospital
-
接触:
- Liangchuan Chen
- 电话号码:+86 13956556381
- 邮箱:aqslyy@163.com
-
Tongling、Anhui、中国
- 尚未招聘
- Tongling People's Hospital
-
接触:
- Ying Zhang
- 电话号码:+86 18005669636
- 邮箱:tlph@mail.wh.ah.cn
-
-
Guizhou
-
Zunyi、Guizhou、中国
- 尚未招聘
- Affiliated Hospital of Zunyi Medical College
-
接触:
- Xianping Long
- 电话号码:+86 13885294999
- 邮箱:longxianping1201@163.com
-
-
Hubei
-
Wuhan、Hubei、中国
- 尚未招聘
- Wuhan Asia General Hospital
-
接触:
- Hongwei Han
- 电话号码:+86 15327298622
- 邮箱:wuhanagh@163.com
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200336
- 招聘中
- Tong Ren Hospital, Shanghai Jiaotong University School of Medicine
-
接触:
- Zhaohui Qiu
- 电话号码:+862152039999
- 邮箱:qzh3503@shtrhospital.com
-
Shanghai、Shanghai Municipality、中国
- 尚未招聘
- Fudan University affiliated Huadong Hospital
-
接触:
- Zhengqi Kong
- 电话号码:+86 13816620347
- 邮箱:huadongtexu@163.com
-
Shanghai、Shanghai Municipality、中国
- 尚未招聘
- Shanghai Jiaotong University affiliated Shanghai Ninth People's Hospital
-
接触:
- Zongqi Zhang
- 电话号码:+86 18049827281
- 邮箱:zqzhang_scdc@126.com
-
Shanghai、Shanghai Municipality、中国
- 尚未招聘
- Shanghai Jiaotong University affiliated Shanghai Sixth People's Hospital
-
接触:
- Yisheng Pan
- 电话号码:+86 13817273883
- 邮箱:shlygjyl@163.com
-
Shanghai、Shanghai Municipality、中国
- 尚未招聘
- Shanghai University of Traditional Chinese Medicine affiliated Putuo Hospital
-
接触:
- Zongjun Liu
- 电话号码:+86 19821577439
- 邮箱:lzj72@126.com
-
Shanghai、Shanghai Municipality、中国
- 尚未招聘
- Tongji University School of Medicine affiliated Tongji University
-
接触:
- Bing Sun
- 电话号码:+86 13918324334
- 邮箱:woowoocncn@163.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥18 years
- Indication for permanent pacemaker implantation, including:
- Sinus node dysfunction, defined as at least one of the following:
- Symptomatic sinus bradycardia
- Tachy-brady syndrome
- Chronotropic incompetence
- Sinus pause / arrest
- Atrioventricular block (if present); if ventricular pacing is required, left bundle branch area pacing is planned
- Expected survival >1 year
- Panned implantation of a device capable of detecting atrial high-rate episodes
- Willing and able to provide informed consent
Exclusion Criteria:
- Persistent atrial fibrillation (AF) (>7 days), long-standing persistent AF, permanent AF, or prior atrioventricular node ablation
- Prior cardiac implantable electronic device (CIED) requiring replacement, upgrade, or revision
- Indication for cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT-D)
- Prior cardiac surgery, severe hepatic or renal dysfunction, or other life-threatening systemic diseases
- Acute myocardial infarction within 3 months before enrollment
- Persistent left superior vena cava or dextrocardia
- Pregnant or breastfeeding women, or women of childbearing potential not using effective contraception
- Participation in another clinical trial that may interfere
- Any condition that, in the opinion of the investigator, makes participation unsuitable
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:PSB pacing
Patients were randomly assigned to receive posterosuperior bundle pacing for atrial pacing during regular pacemaker implantation procedures. |
Atrial pacing lead implanted at the posterosuperior bundle region. Left bundle branch area pacing will be applied if ventricular pacing is necessary. |
|
有源比较器:RAA pacing
Patients were randomly assigned to receive right atrial appendage pacing for atrial pacing during regular pacemaker implantation procedures. |
Atrial pacing lead implanted at the right atrial appendage. Left bundle branch area pacing will be applied if ventricular pacing is necessary. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of atrial fibrillation
大体时间:From implantation to regular follow-ups up to 24 months
|
Incidence of atrial fibrillation ≥ 6 minutes during follow-ups |
From implantation to regular follow-ups up to 24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Atrial high-rate episodes
大体时间:From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
AF burden
大体时间:From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
eGFR
大体时间:At baseline, before discharge, and 6 - month follow-up
|
At baseline, before discharge, and 6 - month follow-up
|
|
|
All-cause mortality
大体时间:From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Cardiovascular death
大体时间:From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Intrinsic P-wave duration
大体时间:At baseline and regular follow-ups up to 24 months, when intrinsic atrial rhythm is assessable
|
Measured from the onset of the P wave to the end |
At baseline and regular follow-ups up to 24 months, when intrinsic atrial rhythm is assessable
|
|
Paced P-wave duration
大体时间:From implantation to regular follow-ups up to 24 months
|
Measured from the pacing stimulus to P wave end duration |
From implantation to regular follow-ups up to 24 months
|
|
Left ventricular ejection fraction (LVEF)
大体时间:At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left atrial diameter (LAD)
大体时间:At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Right atrial diameter (RAD)
大体时间:At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left ventricular end-systolic diameter (LVESD)
大体时间:At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left ventricular end-diastolic diameter (LVEDD)
大体时间:At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
E/e'
大体时间:At baseline, 6-, 12- , 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12- , 24-month follow-ups
|
|
Mitral regurgitation severity
大体时间:At baseline, 6-, 12- , 24-month follow ups
|
Standard transthoracic echocardiographic measurement using standard semi-quantitative grading (none/trace, mild, moderate, or severe) |
At baseline, 6-, 12- , 24-month follow ups
|
|
Tricuspid regurgitation severity
大体时间:At baseline, 6-, 12-, 24- month follow-ups
|
Standard transthoracic echocardiographic measurement using standard semi-quantitative grading (none/trace, mild, moderate, or severe) |
At baseline, 6-, 12-, 24- month follow-ups
|
|
NT-pro BNP
大体时间:At baseline, before discharge, and 6-month follow-up
|
Standard transthoracic echocardiographic parameter |
At baseline, before discharge, and 6-month follow-up
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Atrial pacing capture threshold
大体时间:From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Atrial sensing amplitude
大体时间:From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Atrial pacing output
大体时间:From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Procedural complications
大体时间:Perioperative
|
Safety Outcome |
Perioperative
|
|
Postoperative adverse events
大体时间:From implantation to regular follow-ups up to 24 months
|
Safety Outcome, including lead-related complications, thromboembolic events, etc. |
From implantation to regular follow-ups up to 24 months
|
|
Paced P-wave morphology
大体时间:From implantation to regular follow-ups up to 24 months
|
positive, negative, notched, and biphasic |
From implantation to regular follow-ups up to 24 months
|
|
Intrinsic P-wave morphology
大体时间:At baseline, implant, and regular follow-ups up to 24 months when intrinsic atrial rhythm is assessable
|
positive, negative, notched, and biphasic |
At baseline, implant, and regular follow-ups up to 24 months when intrinsic atrial rhythm is assessable
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- PSB-AF
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.